摘要
目的探讨早期静脉应用双磷酸盐对晚期乳腺癌生存及骨转移的影响作用。方法选择2003年6月至2011年6月在中国石油中心医院住院治疗的50例晚期乳腺癌患者作为研究对象,根据诊断情况分为两组:早期治疗组(21例)患者在确诊骨转移之前即开始应用双磷酸盐治疗,晚期治疗组(29例)在确诊骨转移之后开始应用双磷酸盐治疗。比较两组患者无进展生存期、总生存期、骨转移发生率及发生时间、不良反应发生情况。结果早期治疗组患者的无进展生存期及总生存期显著长于晚期治疗组(χ2=4.567,3.924,P<0.05),早期治疗组患者的骨转移发生率显著低于晚期治疗组(χ2=3.954,P=0.046),确诊骨转移时间(20个月)显著晚于晚期治疗组(17个月)(χ2=4.644,P=0.031);两组患者治疗相关不良反应发生情况比较,差异无统计学意义(P>0.05)。结论早期应用双磷酸盐治疗晚期乳腺癌,能够延长患者的无进展生存期及总生存期,减少并推迟骨转移发生,且不增加不良反应发生率,值得临床推广应用。
Objective To evaluate theeffect of early intravenous bisphosphonates（ BPs） on the survival and bone metastasis occurrence in treatment of advanced breast cancer. Methods A total of50 patients with advanced breast cancerhospitalization in Chinese Petroleum Center Hospital during Jun. 2003 to Jun. 2011 were included in the study. In early treatment group（ 21 cases）,BPs application started before bone metastases diagnosis,while in the late treatment group（ 29 cases）,BPs was given after the diagnosis of bone metastases. Progression-free survival（ PFS）,overall survival（ OS）,the incidence and bone metastases occurrence time,adverse reactions of the two groups were compared. Results In early treatment group,the median PFS and OS were significantly extended than those in the late treatment group（ χ2= 4. 567,3. 924,P〈 0. 05）,bone metastases incidence was reduced,the difference was statistically significant（ χ2= 3. 954,P = 0. 046）. The median time of bone metastases occurrence was significantly delayed in the early treatment group patients（ 20 months vs 17 months,χ2= 4. 644,P = 0. 031）,there was no statistically significant between the treatment-related adverse reactions of the two groups（ P〉0. 05）. Conclusion Early application of bisphosphonate in treatment of advanced breast cancer may prolong PFS and OS,decrease and delay bone metastases,and do not increase the adverse reactions,thus is worthy for spreading in clinical application.
出处
《医学综述》
2014年第22期4194-4196,共3页
Medical Recapitulate
基金
廊坊市科学技术研究与发展计划项目(2012013080)
关键词
晚期乳腺癌
早期应用
双磷酸盐
骨转移
恶性肿瘤
Advanced breast cancer
Early application
Bisphosphonates
Bone metastases
Malig-nancies
